| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Andreas E. Albers | Q56953041 |
| P2093 | author name string | T K Hoffmann | |
| A M Kaufmann | |||
| J P Klussmann | |||
| P2860 | cites work | Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy | Q83006286 |
| [Human papillomavirus and cancer of the oropharynx. Molecular interaction and clinical implications] | Q83298961 | ||
| Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18 | Q83925050 | ||
| Preliminary HPV vaccine results for women older than 25 years | Q84012251 | ||
| Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer | Q95720944 | ||
| Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review | Q22306450 | ||
| Global cancer statistics, 2002 | Q27860562 | ||
| Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial | Q28236008 | ||
| Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus | Q28261838 | ||
| Papillomaviruses and cancer: from basic studies to clinical application | Q29614745 | ||
| Epidemiologic classification of human papillomavirus types associated with cervical cancer | Q29616213 | ||
| Human papillomavirus is a necessary cause of invasive cervical cancer worldwide | Q29617514 | ||
| CO(2) laser treatment in 244 patients with respiratory papillomas | Q31011270 | ||
| Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus | Q31132352 | ||
| Evidence for a causal association between human papillomavirus and a subset of head and neck cancers | Q33180284 | ||
| Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus | Q33197530 | ||
| Nobel price for vaccination against cervical cancer: current data and guidelines | Q33433442 | ||
| Immunotherapeutic strategies for cervical squamous carcinoma | Q33541956 | ||
| Human papillomavirus in head and neck squamous cell carcinoma: are some head and neck cancers a sexually transmitted disease? | Q33635781 | ||
| Potential strategies utilised by papillomavirus to evade host immunity | Q33683360 | ||
| Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers | Q34221597 | ||
| Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers | Q34286359 | ||
| Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). | Q34332463 | ||
| The epidemiology of human papillomavirus infections | Q34400853 | ||
| Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial | Q34415030 | ||
| Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination | Q47637442 | ||
| Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia | Q47650204 | ||
| Incidence, age at onset, and potential reasons of malignant transformation in recurrent respiratory papillomatosis patients: 20 years experience | Q47838747 | ||
| Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. | Q50857924 | ||
| Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. | Q51029416 | ||
| Molecular transformation of recurrent respiratory papillomatosis: viral typing and p53 overexpression. | Q51675025 | ||
| Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. | Q51820508 | ||
| Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. | Q52014824 | ||
| HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients. | Q54690022 | ||
| Epidemiology of Genital Human Papillomavirus Infection | Q56144870 | ||
| High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma | Q56532872 | ||
| Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites | Q56902548 | ||
| Epidemiology of Acquisition and Clearance of Cervical Human Papillomavirus Infection in Women from a High‐Risk Area for Cervical Cancer | Q57089472 | ||
| Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx | Q58226228 | ||
| Human Papillomavirus and Risk of Laryngeal Cancer | Q58226261 | ||
| Carcinogenicity of human papillomaviruses | Q58296516 | ||
| Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia | Q58813797 | ||
| Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6 | Q60321491 | ||
| Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine | Q60321494 | ||
| Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia | Q60441062 | ||
| Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity | Q61626183 | ||
| Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia | Q61626254 | ||
| Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter | Q61626294 | ||
| Head and neck cancer | Q70522684 | ||
| Head and neck cancer | Q70725728 | ||
| Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus | Q73804558 | ||
| Poor antibody response against human papillomavirus in adult-onset laryngeal papillomatosis | Q73840547 | ||
| Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer | Q74200096 | ||
| Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts | Q74607911 | ||
| Perinatal transmission of human papillomavirus from gravidas with latent infections | Q77360602 | ||
| Ano-genital neoplasia in renal transplant patients | Q77739160 | ||
| Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts | Q78024457 | ||
| Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers | Q79078502 | ||
| A causal role for human papillomavirus in head and neck cancer | Q80068307 | ||
| Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease | Q81167479 | ||
| HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial | Q34461719 | ||
| Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. | Q34534523 | ||
| Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial | Q34580726 | ||
| Activity of HspE7, a novel immunotherapy, in patients with anogenital warts | Q34635099 | ||
| Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial | Q34749494 | ||
| Recurrent respiratory papillomatosis: indication for HPV vaccination? | Q34974723 | ||
| Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential | Q35015851 | ||
| Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). | Q35047009 | ||
| A review of human papillomavirus vaccines from basic science to clinical trials | Q35109351 | ||
| Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. | Q35113700 | ||
| Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments | Q35210588 | ||
| Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and -negative women | Q35220992 | ||
| Natural history and epidemiological features of genital HPV infection | Q35235313 | ||
| ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial | Q35644707 | ||
| Role of human papillomavirus in the development of head and neck squamous cell carcinomas | Q35821717 | ||
| Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population | Q35932976 | ||
| Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III | Q36052694 | ||
| Human papillomavirus (HPV) in head and neck cancer | Q36064309 | ||
| Clinical implications of human papillomavirus in head and neck cancers | Q36416436 | ||
| Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. | Q36483341 | ||
| Prevention of recurrent respiratory papillomatosis: role of HPV vaccination | Q36555070 | ||
| Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. | Q36566884 | ||
| Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer | Q36616391 | ||
| Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis | Q36647828 | ||
| Task force on recurrent respiratory papillomas. A preliminary report | Q36671129 | ||
| Human papillomavirus in laryngeal papillomas and in adjacent normal epithelium | Q36827766 | ||
| Therapeutic vaccination for HPV induced cervical cancers | Q36878779 | ||
| Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. | Q36898605 | ||
| A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women | Q36980796 | ||
| Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression | Q37109165 | ||
| AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention | Q37340445 | ||
| Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasia | Q37518473 | ||
| Therapeutic human papillomavirus vaccination | Q37580636 | ||
| Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial | Q37859219 | ||
| Clonal history of papillomavirus-induced dysplasia in the female lower genital tract | Q38439713 | ||
| Human papillomavirus and prognoses of patients with cancers of the upper aerodigestive tract | Q38468802 | ||
| Age-dependence of human papillomavirus DNA presence in oral squamous cell carcinomas | Q39113986 | ||
| Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins | Q39389688 | ||
| Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma | Q40079450 | ||
| Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial | Q40312191 | ||
| Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. | Q40344942 | ||
| T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx | Q40351911 | ||
| Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients | Q40570530 | ||
| Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. | Q40582374 | ||
| A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. | Q40746658 | ||
| Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-dependent peptide transport | Q40777595 | ||
| Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. | Q40889921 | ||
| T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease | Q41888065 | ||
| Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer | Q43413399 | ||
| Laryngeal papillomas: classification and course | Q43523425 | ||
| Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck | Q43571689 | ||
| Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia | Q43700608 | ||
| Immunological events in regressing genital warts | Q43760914 | ||
| The natural history of type-specific human papillomavirus infections in female university students. | Q43919306 | ||
| Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities | Q44113435 | ||
| Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection | Q44238190 | ||
| CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia | Q44310727 | ||
| A controlled trial of a human papillomavirus type 16 vaccine | Q44366335 | ||
| Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia | Q44653310 | ||
| Human papillomavirus in oral exfoliated cells and risk of head and neck cancer | Q44802936 | ||
| Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia | Q45142471 | ||
| Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine | Q45212845 | ||
| Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women | Q45396774 | ||
| Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions | Q45399390 | ||
| Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). | Q45400945 | ||
| Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial | Q45552005 | ||
| Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. | Q45729906 | ||
| Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus | Q45732140 | ||
| A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. | Q45769906 | ||
| The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. | Q45995213 | ||
| Cidofovir induces an increase in levels of low-risk and high-risk HPV E6. | Q46089829 | ||
| Juvenile laryngeal papillomatosis--immunisation with the polyvalent vaccine gardasil | Q46401965 | ||
| A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. | Q46564278 | ||
| A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals | Q46732942 | ||
| Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination | Q46803971 | ||
| The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck | Q46920694 | ||
| Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck | Q47406529 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | German | Q188 |
| P921 | main subject | therapeutic vaccine | Q105212712 |
| human papilloma virus | Q69999790 | ||
| P304 | page(s) | 778-790 | |
| P577 | publication date | 2010-08-01 | |
| P1433 | published in | HNO | Q27711112 |
| P1476 | title | [Prophylactic and therapeutic vaccines against human papilloma virus] | |
| P478 | volume | 58 |
| Q36529848 | Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer |
| Q43900422 | Microlaryngoscopy and phonomicrosurgery |
| Q56956550 | Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer |
| Q36529843 | Systemic therapy strategies for head-neck carcinomas: Current status |
Search more.